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It has been reported that anti-dengue antibodies at subneutralizing concentrations augment dengue virus
infection of monocytic cells. This is due to the increased uptake of dengue virus in the form of virus-antibody
complexes by cells via Fcl, receptors. We analyzed the effects of recombinant human gamma interferon
(rIFN-y) on dengue virus infection of human monocytic cells. U937 cells, a human monocytic cell line, were
infected with dengue virus in the form of virus-antibody complexes after rIFN-y treatment. Pretreatment of
U937 cells with rIFN-y resulted in a significant increase in the number of dengue virus-infected cells and in the
yield of infectious virus. rIFN-y did not augment dengue virus infection when cells were infected with virus in
the absence of anti-dengue antibodies. Gamma interferon (IFN--y) produced by peripheral blood lymphocytes
from dengue-immune donors after in vitro stimulation with dengue antigens also augmented dengue virus
infection of U937 cells. IFN--y did not augment dengue virus infections when cells were infected with virus in
the presence of F(ab')2 prepared from anti-dengue immunoglobulin G. Human immunoglobulin inhibited
IFN-y-induced augmentation. IFN-y increased the number of Fc,, receptors on U937 cells. The increase in the
percentage of dengue antigen-positive cells correlated with the increase in the number of Fcl, receptors after
rIFN--y treatment. These results indicate that IFN-y-induced augmentation of dengue virus infection is Fc,,
receptor mediated. Based on these results we conclude that IFN-'y increases the number of Fc,, receptors and
that this leads to an augmented uptake of dengue virus in the form of dengue virus-antibody complexes, which
results in augmented dengue virus infection.
Dengue is a tropical illness caused by dengue virus infec-
tion of humans and is transmitted by mosquitoes. The
disease is endemic over a large part of Southeast Asia, the
Pacific, Africa, and Central America. Clinically, infection
with dengue virus presents in two major forms, dengue fever
and dengue hemorrhagic fever-dengue shock syndrome
(DHF-DSS). Dengue fever is a self-limited disease and
represents most cases of dengue. In some cases, however,
patients develop severe complications, DHF-DSS, which
are life threatening. From 1980 through 1985, 500,000 cases
of DHF-DSS were reported worldwide (16).
Human monocytes support active replication of dengue
virus in vivo (11). Studies done by Halstead et al. have
shown that monocytes are infected to a much greater extent
in vitro in the presence of anti-dengue virus antibody (7, 10).
This is due to the increased uptake by monocytes of dengue
virus in the form of dengue virus-antibody complexes via
FcY receptors (4, 10). This phenomenon is referred as
immune enhancement. Interestingly, most cases of DHF-
DSS occur during secondary dengue infections when there
are dengue virus antibodies present (2, 8, 9), and immune
enhancement may play an important role in the pathogenesis
of DHF-DSS (18). We have reported that T lymphocytes of
dengue antibody-positive donors produce high titers of
gamma interferon (IFN--y) after stimulation with dengue
antigens in vitro (I. Kurane, B. L. Innis, A. Nisalak, C.
Hoke, S. Nimmannitya, A. Meager, and F. A. Ennis,
submitted for publication). Therefore, it can be expected
that IFN--y is produced in vivo during secondary dengue
infections. It has been reported that IFN--y increases the
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number of FcY receptors on human monocytes and monocy-
tic cell lines (6, 17). In this study we investigated the effect of
IFN--y on dengue virus infection of U937 cells, a human
monocytic cell line. IFN--y augmented dengue virus infection
of U937 cells when cells were infected in the presence of
anit-dengue antibody. The augmenting effect of IFN-y was
Fc,, receptor dependent. We conclude that IFN--y increases
the number of FcY receptors and that this results in the
augmented infection of the cells by dengue virus-antibody
complexes.
MATERIALS AND METHODS
Virus and antibody. Dengue virus type 2, New Guinea C
strain, was used for infection. The virus was supplied by
Walter E. Brandt of the Walter Reed Army Institute of
Research, Washington, D.C. The virus was passed in mouse
brain and then propagated in mosquito cells (C6/36) as
previously described (14). The titer of the virus pool used in
these experiments was 107 PFU/ml in Vero cells as deter-
mined by previously described methods (12). Ascitic fluid
from mice hyperimmunized with dengue virus type 2 was
used as a source of anti-dengue virus type 2 antibody. This
antibody was also supplied by Walter E. Brandt. The titer of
this antibody was 1:1,024 as determined by a plaque neutral-
ization test (14). Hyperimmune ascitic fluid was heated at
56°C for 30 min to destroy complement activity before use.
Cells cultures. U937, a monocytic cell line that was derived
from a patient with histiocytic lymphoma (19), was used.
Cells were cultured in RPMI 1640 medium (Flow Laborato-
ries, McLean, Va.) supplemented with 10% fetal calf serum
(GIBCO Laboratories, Grand Island, N.Y.).
IFNs and anti-IFN antibodies. Human recombinant IFN-,y
(rIFN-y; Hoffman-LaRoche, Inc., Nutley, N.J.) and human
lymphoblastoid IFN-a (Lee-Biomolecular Research, San
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Diego, Calif.) were used. For neutralization experiments, a
monoclonal antibody to human IFN--y (Interferon Sciences,
New Brunswick, N.J.) and a rabbit polyclonal antibody to
IFN-a (Interferon Sciences) were used.
Treatment of cells with human y-globulin. U937 cells were
incubated with 10 mg of of human immunoglobulin (-y-
globulin) (Sigma Chemical Co., St. Louis, Mo.) per ml or
bovine albumin fraction V powder (GIBCO) in RPMI for 20
min at 4°C. The cells were washed three times and then
infected by dengue virus-antibody complexes. The human
y-globulin used in the experiments had no neutralizing
activity (<1:10) for dengue virus type 2 when it was tested in
a plaque-neutralization assay at a concentration of 10 mg/ml.
Culture fluid of PBMC stimulated with dengue antigen.
Peripheral blood mononuclear cells (PBMC) from a donor
who previously had been infected with dengue virus type 3
and subsequently developed antibodies to dengue virus type
3 were stimulated with a dengue virus type 3 antigen
preparation or control antigen for 7 days. This antigen was
prepared from dengue virus-infected Vero cells that were
treated with 0.025% glutaraldehyde and sonicated. Control
antigen was prepared from uninfected Vero cells, which
were also glutaraldehyde treated and sonicated. Culture
fluids were tested for IFN--y and IFN-a by Anthony Meager,
London, by using a radioimmunoassay with specific mono-
clonal antibodies for human IFN--y and IFN-a (15).
Infection of cells with dengue virus. U937 cells were
washed once in RPMI 1640 containing 1% fetal calf serum
and suspended to a concentration of 106 cells per 0.1 ml.
They were then incubated with dengue virus type 2 or with
dengue virus type 2-antibody complexes for 2 h. These
virus-antibody complexes were made before infection by
adding 10 ,ul of anti-dengue virus type 2 mouse ascites fluid
at a dilution of 1:200 to 5 x 106 PFU of dengue virus type 2
in 0.5 ml and were incubated for 1 h at 4°C. The multiplicity
of infection (MOI) of the virus inoculum was 5 PFU per cell.
Cells were washed twice after 2 h of incubation with virus or
virus-antibody complexes and then cultured at a concentra-
tion of 2 x 105 cells per ml in RPMI 1640 containing 10%
fetal calf serum for 24 h. Cells were then stained for the
presence of dengue viral antigen by immunofluorescence as
previously described (14). The mouse anti-dengue virus type
2 serum described above and a fluorescein isothiocyanate-
conjugated sheep anti-mouse imtnunoglobulin G (IgG) anti-
body (Cappel Laboratories, Malvern, Pa.) were used.
Preparation of F(ab')2 from anti-dengue virus type 2 IgG.
F(ab')2 was prepared from anti-dengue virus type 2 mouse
ascites fluid with an Immuno Pure F(ab')2 preparation kit
(Pierce Chemical Co., Rockland, Ill.). Mouse ascites fluid
was diluted 1:2 with the binding buffer (pH 8.2), and 1 ml of
the diluted fluid was applied to a 1-ml column of immobilized
protein A. The column was washed with 15 column volumes
of the binding buffer. IgG was eluted with 5 column volumes
of the elution buffer (pH 2.8). Eluted IgG was dialyzed
against 20 mM sodium acetate at pH 4.2 and concentrated to
an IgG concentration of 20 mg/ml with a minicon-A25
(Amicon Corp., Danvers, Mass.). Then 10 mg of IgG was
treated with 12.5% immobilized pepsin (Pierce) in 1 ml of 20
mM sodium acetate (pH 4.2) at 37°C for 4 h. The crude digest
(10 mg in 3 ml) was applied to a 3-ml column of immobilized
protein A, and F(ab')2 was eluted with 6 ml of the binding
buffer. IgG and F(ab')2 were dialized against phosphate-
buffered saline (pH 7.4) at 4°C for 72 h. The purity of F(ab')2
and IgG was examined by using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. F(ab')2 did not contain
any detectable IgG. F(ab')2 and purified IgG were concen-
trated to a concentration of 1 mg/ml with a minicon-A25. The
neutralizing antibody titers of purified IgG and F(ab')2 at 1
mg/ml were 1:320 and 1:160, respectively, determined by a
plaque neutralization test for dengue virus type 2 (14).
Detection of Fc,, receptors. Fc receptors were analyzed by
quantitative flow cytometry with a monoclonal antibody,
MAb 32, kindly provided by Paul Guyre of Dartmouth
Medical School, Hanover, N.H. (1). MAb32 is an IgGl
antibody which reacts with the high-affinity Fc receptor on
U937 cells and human monocytes (1). Cells (2.5 x 106) were
incubated with MAb32 at a final dilution of 1:3 in 150 RI of
RPMI 1640 containing 40 mg of human -y-globulin per ml at
4°C for 2 h. Cells were washed twice in phosphate-buffered
saline containing 2% bovine serum albumin and incubated
with 100 ,ul of FITC-conjugated goat F(ab')2 anti-mouse IgG
antibody (Caltag Laboratories, South San Francisco, Calif.)
at a final dilution of 1:30 at 4°C for 2 h. Cells were then
washed two times in phosphate-buffered saline containing
2% bovine serum albumin and fixed with 2% paraformalde-
hyde. Stained cells were analyzed with a fluorescence-
activated cell sorter (Coulter 753; Coulter, Hialeah, Fla.).
Quantitative fluorescein microbeads (Flow Cytometry Stan-
dards Corp., Research Triangle Park, N.C.) were used for
calibration to convert the fluorescence intensity values ob-
tained from the flow cytometer into the number of molecules
of second antibody bound per cell. Since the number of
molecules of second antibody bound per cell is expected to
be proportional to the number of molecules of the first
antibody, which is the MAb32 to the high-affinity Fc recep-
tor, the number of second antibody molecules bound per cell
can serve as a relative measurement of the number of Fc
receptors per cell.
RESULTS
IFN--y augments dengue virus infection of U937 cells in the
presence of anti-dengue antibody. U937 cells were incubated
with 100 U of rIFN--y per ml for 24 h and then infected with
dengue virus at an MOI of 5 PFU per cell in the presence of
anti-dengue mouse serum. The percentage of dengue anti-
gen-positive cells was determined by indirect immunofluo-
rescence staining 24 h after infection. Anti-dengue serum at
final dilutions of 1:103, 1:104, and 1:105 augmented infection
of nontreated U937 cells and further augmented dengue virus
infection when U937 cells were pretreated with rIFN--y (Fig.
1). Normal mouse serum, which did not contain detectable
levels of anti-dengue antibody, did not augment dengue virus
infection of the nontreated or the IFN--y-treated U937 cells
(data not shown). Based on these results, we decided to use
anti-dengue serum at a final dilution of 1:104 in the following
experiments.
U937 cells were incubated with variable amounts of
rIFN-y for 24 h and infected with dengue virus at an MOI of
5 PFU per cell in the presence of the anti-dengue mouse
serum at a final dilution of 1:104. Pretreatment of U937 cells
with rIFN--y at concentrations from 1 to 10,000 U/ml in-
creased the percentage of dengue antigen-positive cells. The
percentage of antigen-positive cells reached a maximum
level by pretreatment with IFN--y at 100 U/ml (Fig. 2). When
U937 cells were infected with dengue virus in the absence of
anti-dengue antibody, pretreatment with rIFN--y did not
increase the percentage of antigen-positive cells (1 to 3%
without rIFN--y treatment and 1 to 4% with rIFN-y treat-
ment). Pretreatment of U937 cells with 100 U of rIFN--y per
ml also increased dengue virus titers in the culture fluids
when cells were infected with virus in the presence of
VOL. 62, 1988 3929
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FIG. 1. Effect of dilution of anti-dengue serum on dengue virus
infection of U937 cells. U937 cells were incubated with or without
100 U of rIFN-y per ml for 24 h and infected with dengue virus at an
MOI of 5 PFU/ml in the presence of variable dilutions of anti-dengue
mouse serum. The percentage of dengue antigen-positive cells was
determined by indirect immunofluorescence staining 24 h after
infection. Symbols: 0, U937 cells pretreated with rIFN-,y; 0,
nontreated U937 cells. The percentage of antigen-positive cells was
compared between IFN-_y-pretreated cells and nontreated cells at
same dilutions of anti-dengue virus type 2 serum. P < 0.001 at serum
dilutions of lo-3, 10-, and i0-5; P < 0.05 at serum dilution of 10-6.
P > 0.05 (not significant) at a serum dilution of 10-2 and with no
serum.
antibody but not when cells were infected in the absence of
antibody (Table 1).
IFN--y produced by dengue-immune lymphocytes after stim-
ulation with dengue antigen augments dengue virus infection
of U937 cells. IFN--y produced by human lymphocytes in
vitro was used in the following experiments. PBMC from a
dengue antibody-positive donor were cultured with dengue
antigen for 7 days, and the culture fluid was collected. The
culture fluid contained 650 U of IFN-y per ml and no
TABLE 1. Virus titers in the culture fluids of dengue
virus-infected U937 cells pretreated with IFN-ya
Virus titer (PFU/ml)
IFN-y (U/ml) With anti- Without
dengue antibody antibody
0 5.0 x 103 3.5 x 102
1 4.5 x 104 4.0 x 102
10 6.0 x 104 6.5 x 102
100 9.0 x 104 7.0 x 102
1,000 1.0 x 105 6.0 x 102
aU937 cells were incubated with various concentrations of rIFN-,y for 24 h
and infected with dengue virus at an MOI of 5 PFU per cell in the presence of
anti-dengue mouse serum at final dilution of l0-4 or in the absence of
antiserum. Cells were cultured at 3 x 105 cells per ml in RPMI 1640 containing
10% fetal calf serum for 24 h. Titers of dengue virus contained in the culture
fluids were determined by using a plaque titration assay.
detectable IFN-a as determined by radioimmunoassays spe-
cific for human IFN--y and IFN-ao. U937 cells were incubated
for 24 h with various dilutions of this culture fluid and
infected with dengue virus-antibody complexes. The diluted
culture fluids from lymphocytes of the dengue-immune do-
nor that had been stimulated with dengue antigens and
contained 10 or 100 U of IFN--y per ml augmented dengue
virus infection of U937 cells as well as recombinant IFN--y
(Table 2).
Anti-IFN-y antibody inhibits IFN-y-induced augmentation
of dengue virus infections. To confirm that the IFN--y con-
tained in the culture fluid is responsible for the augmented
dengue virus infection shown in Table 2, culture fluid which
contained 10 U of IFN--y per ml was incubated with a
monoclonal anti-IFN--y antibody and then used to treat U937
cells. Culture fluid pretreated with an anti-IFN--y antibody
did not augment dengue virus infection, but the culture fluid
pretreated with an anti-IFN-cx antibody did augment infec-
tion (Table 3). We also tried to block the effect of rIFN--y by
using a monoclonal anti-IFN--y antibody to confirm that the
rIFN-y-induced augmentation of infection was due to IFN--y
and not to other substances derived from the production of
this rIFN-y in Escherichia coli (3). U937 cells were pretrea-
8 50-
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FIG. 2. Dengue virus infection of U937 cells pretreated with
IFN--y. U937 cells were incubated with variable concentrations of
IFN-y for 24 h and then infected with dengue virus-antibody
complexes at an MOI of 5 PFU per cell. The percentage of dengue
antigen-positive cells was determined by indirect immunofluores-
cent staining 24 h after infection. The percentage of antigen-positive
cells was compared between IFN--y-pretreated cells and nontreated
cells. P < 0.001 at IFN-y concentration of 1, 10, 100, 1,000, and
10,000 U/ml. P > 0.05 (not significant) at 0.01 and 0.1 U/ml.
TABLE 2. Culture fluid of dengue-immune donor PBMC
stimulated with dengue antigen augments dengue
virus infection of U937 cells
Source of IFN-y Titer (U/mI) % of dengue
antigen-positive cells"
None 0 11.5
Dengue culture fluid" 1 13.2'
10 21.6
100 32.6e
Recombinant IFN--y 100 42.6e
"U937 cells were incubated with rIFN-y or with dengue virus-stimulated
culture fluid for 24 h and then infected with dengue virus-antibody complexes
at an MOI of 5 PFU per cell. The percentage of dengue antigen-positive cells
was determined by indirect immunofluorescence 24 h after infection. The
percentage of antigen-positive cells was compared between IFN-y-pretreated
cells and nontreated cells.
b The PBMC from a dengue antibody-positive donor were cultured with
dengue antigen for 7 days, and culture fluid was collected. This culture fluid,
which contained IFN-y at a titer of 650 U/ml and no detectable IFN-a as
determined by radioimmunoassay, was diluted to contain 1, 10, or 100 U of
IFN per ml for pretreatment of U937 cells.
' P > 0.05 (not significant).
d p < 0.01.
e P < 0.001.
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TABLE 3. IFN--y contained in the culture fluid of PBMC is
responsible for augmenting dengue virus infection of U937 cells
Source of IFN--y Antibodies' % of dengueantigen-positive cells'
Dengue culture fluidc None 66.0
Anti-IFN-y 20.5
Anti-IFN-a 59.6
Control culture fluidd None 20.9
None None 15.0
Anti-IFN-y 16.4
Anti-IFN-ot 12.1
a Dengue culture fluid which contained IFN-y was duluted to 10 U/ml and
then incubated with 1,000 U of monoclonal anti-IFN-y per ml and 2,000 U of
anti-IFN-ot at 4'C for 2 h.
b U937 cells were incubated with culture fluids for 24 h and infected with
dengue virus-antibody complexes at an MOI of 5 PFU per cell. The percent-
age of dengue antigen-positive cells was determined by indirect immunofluo-
rescent staining 24 h after infection.
' Dengue culture fluid was obtained as described in footnote b of Table 2
and was diluted to contain 10 U of IFN-y per ml.
d PBMC of the same donor were cultured with a control antigen for 7 days,
and a culture fluid was collected. This culture fluid, which contained no
detectable IFN-y or IFN-ca, was diluted similarly.
ted with 10 U of rIFN-y which had been incubated with a
monoclonal IFN--y antibody or a polyclonal anti-IFN-ax
antibody per ml. An anti-IFN-y antibody inhibited the aug-
menting effect of rIFN--y, but anti-IFN-ao antibody had no
effect (data not shown). These results confirm that IFN--y is
responsible for the augmentation of dengue virus infection
shown in Table 2 and Fig. 1 and 2.
Human y-globulin blocks IFN-ly-induced augmentation of
dengue virus infection. It has been reported that IFN--y
increases Fcy receptors on U937 cells (6, 17). We tried to
determine whether the IFN--y-induced augmentation of den-
gue virus infection was Fc receptor mediated. U937 cells
that had been treated with 100 U of rIFN-y per ml for 24 h
were incubated with -y-globulin at 4°C for 20 min. Cells were
then infected with dengue virus-antibody complexes. -y-
Globulin inhibited infection by dengue virus-antibody com-
plexes of U937 cells that were pretreated with IFN--y,
whereas bovine serum albumin at the same concentration
had no effect (Table 4). These results suggest that the
IFN-y-induced augmentation of dengue virus infection is
mediated by Fcy receptors.
IFN-,y does not augment dengue virus infection of U937 cells
in the presence of the F(ab')2 fraction of anti-dengue IgG
antibody. We then used the F(ab')2 fraction of anti-dengue
IgG to confirm that IFN--y-induced augmentation of dengue
TABLE 4. Inhibition of IFN--y-induced augmentation of dengue
virus infection by human -yglobulina
% of dengue antigen-positive cells
Blocking reagent
IFN-y pretreatment No pretreatment
None 40.8 11.5
y-Globulin 1.8 <1.0
Bovine serum albumin 41.6 11.6
a U937 cells that had been treated with 100 U of rIFN--y per ml for 24 h were
incubated with human y-globulin (10 mg/ml) or bovine serum albumin (10
mg/ml) at 4'C for 20 min. Cells were infected with dengue virus-antibody
complexes at an MOI of 5 PFU per cell. The percentage of dengue antigen-
positive cells was determined by indirect immunofluorescence 24 h after
infection.
TABLE 5. F(ab')2 prepared from anti-dengue IgG does
not augment dengue virus infection of U937 cells
pretreated with IFN--ya
% of dengue antigen-positive cells
Final concn of
IgG and F(ab')2 IFN-y pretreatment No treatment
(,ug/ml)
IgG F(ab')2 IgG F(ab')2
0 1.0 1.0 1.4 1.4
0.001 1.3 1.3 1.0 0.5
0.01 6.2 0.9 3.5 1.5
0.1 36.5b 2.1 9.8b 1.2
1 73.7b 0.4 34.2b 1.2
10 36.5 <0.3 16.8 <0.3
100 11.6' 0.4 7.0c <0.3
a U937 cells were incubated with or without 100 U/ml of rIFN-y for 24 h and
infected with dengue virus at an MOI of 5 PFU/ml in the presence of various
concentrations of purified anti-dengue IgG or F(ab')2 prepared from IgG. The
percentage of dengue antigen-positive cells was determined 24 h after infec-
tion. The percentage of antigen-positive cells was compared between IFN-y-
pretreated cells and nontreated cells at same concentrations of IgG and
F(ab')2-
b p < 0.001.
'P < 0.005. Results were not significant (P > 0.05) except where indicated.
virus infection is FcY receptor mediated. Pretreatment of
U937 cells with IFN--y did not augment infection when cells
were infected with dengue virus in the presence of F(ab')2
prepared from anti-dengue IgG, but IFN-y pretreatment
augmented infection when cells were infected with virus in
the presence of purified anti-dengue IgG at 0.1 to 10 ,ug/ml
(Table 5). This result confirms that the IFN-y-induced aug-
mentation of dengue virus infection is mediated by Fcy
receptors on U937 cells.
Augmentation of dengue virus infection correlates with
increase in the number of Fc,, receptors. We tried to deter-
mine whether there is a correlation between the number of
FcY receptors and the percentage of dengue antigen-positive
cells. U937 cells were incubated with variable concentra-
tions of IFN-y for 24 h and examined for FcY receptor
expression by quantitative fluorescence-activated cell sorter
analysis after exposure to MAb32, which is specific for the
human FcYR1. The percentage of antigen positive cells was
determined 24 h after infection. There was a good correlation
between the percentage of dengue antigen-positive cells and
the number of FcY receptors (Fig. 3). This result is consistent
with those shown in Tables 4 and 5 and indicates that
augmentation of dengue virus infection induced by IFN-y is
mediated by FcY receptors.
DISCUSSION
In this report we demonstrate that IFN--y augments den-
gue virus infection of U937 cells in the presence of anti-
dengue antibodies. This effect is Fcy receptor mediated,
because (i) IFN--y had no augmenting effect on the infection
of U937 cells when cells were infected with dengue virus in
the absence of anti-dengue antibody, (ii) IFN-y did not
augment dengue virus infection when cells were infected
with virus complexed to the F(ab')2 fraction prepared from
anti-dengue IgG, (iii) IFN--y had no augmenting effect when
Fcy receptors on U937 cells were blocked by -y-globulin, and
(iv) there was a good correlation between the percentage of
dengue antigen-positive cells and the number of Fcy recep-
tors on U937 cells. We observed that IFN--y increased the
number of Fcy receptors on U937 cells, as previously
reported by other investigators (6, 17). Based on these
VOL. 62, 1988 3931
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FIG. 3. Correlation between IFN--y increased FcY receptors and
dengue virus infection. U937 cells were incubated with variable
titers of IFN-y for 24 h. Cells were infected with dengue virus-
antibody complexes at an MOI of 5 PFU/cell. The percentage of
dengue antigen-positive cells was determined by indirect immuno-
fluorescent staining 24 h after infection. The relative numbers of FcY
receptors was measured by quantitative fluorescence-activated cell
sorter analysis as described in Materials and Methods.
observations, we conclude that the increase in the number of
Fc,, receptors on U937 cells induced by IFN-y leads to an
augmented uptake of dengue virus in the form of dengue
virus-antibody complexes, which results in a higher percent-
age of dengue virus-infected cells and in higher yields of
infectious dengue virus. IFN--y also augmented dengue virus
infection of human monocytes enriched from peripheral
blood mononuclear cells, when monocytes were infected
with virus in the presence of anti-dengue antibodies. IFN--y
did not augment dengue virus infection of human monocytes
when cells were infected in the absence of antibody (data not
shown).
It has been reported that IFN-a has no or little effect on
the number of Fc, receptors on monocytic cells (6, 17). We
found that IFN-o suppressed dengue virus infection of U937
cells at doses higher than 1 U/ml even when cells were
infected in the presence of anti-dengue antibody (data not
shown). We attribute this suppressive effect to the antiviral
activity of IFN-a. We recently reported that high levels of
IFN-a were produced by dengue virus-infected monocytes
(13) and by HLA DR antigen-positive, non-T lymphocytes
cultured with dengue virus-infected monocytes (12); further-
more the IFN-a produced was active in limiting infection of
human monocytes by dengue virus (12, 13).
It has been hypothesized that increased infection of mo-
nocytes with dengue virus in the form of dengue virus-
antibody complexes may occur in vivo and play an important
role in the pathogenesis of DHF-DSS (8). This is supported
by epidemiological studies, which reported that most cases
of DHF-DSS occur during secondary dengue infections
when anti-dengue antibodies are present (2, 9, 18). We have
reported that IFN--y is produced by previously sensitized
human T lymphocytes after secondary antigenic stimulation
(5, 20). We have also found that the T lymphocytes of
individuals who have antibodies to dengue viruses prolifer-
ate and produce high titers of IFN-y after stimulation with
dengue antigens in vitro (Kurane et al., submitted). The
IFN--y produced by dengue virus stimulation of immune T
cells was active in augmenting dengue virus infection of
U937 cells and human monocytes. Therefore, we hypothe-
size that IFN--y is produced by dengue-specific T lympho-
cytes during secondary dengue infections after stimulation
with conserved dengue antigens and that the IFN--y pro-
duced might contribute to the pathogenesis of DHF-DSS by
enhancing Fc,, receptor expression on human monocytes,
thereby increasing the number of infected monocytes and
the yields of infectious dengue virus in the presence of
anti-dengue virus antibodies.
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